Today: 26 April 2026
CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

CrowdStrike stock steadies premarket after Anthropic’s Claude Code Security rattles cyber shares

New York, Feb 23, 2026, 04:55 EST — Premarket

  • CrowdStrike (CRWD) edged 0.6% higher ahead of the bell, rebounding somewhat after Friday’s nearly 8% tumble.
  • Investors are debating if the emergence of new AI-powered security tools will squeeze certain segments of the cybersecurity software space.
  • CrowdStrike’s results are due March 3; investors will be zeroing in on both guidance and commentary around AI.

CrowdStrike bounced 0.6% to $391 before the bell on Monday, making up just a fraction of Friday’s 7.95% drop. Shares wrapped up last week at $388.60.

This shift is notable—fresh concerns over “AI disruption” have already been driving investors away from pricey software stocks, with cybersecurity now getting caught up too. It’s a critical moment for CrowdStrike, as the chatter lands just before its earnings; a tweak in commentary on demand or the competitive landscape could quickly ripple through shares.

The introduction of a security update to Anthropic’s Claude model set off a wave of selling in cybersecurity stocks on Friday, according to BankInfoSecurity. Cloudflare, Okta, and SailPoint each tumbled between 8% and 9%. The iShares Expanded Tech-Software Sector ETF has now lost about 23% for the year, the report noted.

Anthropic has rolled out Claude Code Security, a tool designed to scan codebases for vulnerabilities and recommend specific fixes—though a human still has to approve any changes. According to the company, “a significant share of the world’s code” could soon be combed over by AI. During internal tests, Anthropic says it surfaced over 500 new high-severity vulnerabilities in major open-source projects. Anthropic

Some investors aren’t worried about CrowdStrike’s platform getting cloned out of the blue. The real concern, they say, is that AI could slash the costs of switching providers. “The risk for big brands is not that someone will recreate Splunk or CrowdStrike overnight,” Shay Michel, managing partner at Merlin Ventures, told Calcalist. AI agents, he said, might drive migration costs “to almost zero.” Meanwhile, Kobi Samboursky, managing partner at Glilot Capital, pointed out that while smaller companies might settle for what Claude offers, large firms won’t be able to skip deep cyber know-how. ctech

The question for the market: just what is getting disrupted here? CrowdStrike’s business spans endpoint and cloud security, along with identity and data protection. Now traders are left parsing whether an AI code scanner is a direct threat to those core offerings—or if it’s more likely to shake up specialized code-testing and supply-chain products instead.

CrowdStrike’s Falcon platform, delivered via subscription, collects data from endpoints, cloud workloads, identities, and outside sources, Reuters notes in its company summary.

CrowdStrike will release its fourth-quarter and full-year fiscal 2026 numbers after the bell on March 3, with a conference call set for 5 p.m. Eastern. The market’s focus: updated guidance and specifics on how CrowdStrike aims to cash in on AI, as competition intensifies in security workflows.

Stock Market Today

  • Alcidion Group's Investment Narrative Holds Steady Around A$0.14 Fair Value
    April 25, 2026, 11:43 PM EDT. Alcidion Group's fair value remains anchored at A$0.1425 per share, with sector dynamics shaping investor outlook. Analyst price targets reflect cautious optimism influenced by product cycles, cash flow, and valuation trends among larger medical technology peers. BTIG highlights the company's stable product cadence and strong free cash flow, while Wells Fargo, Barclays, and Stifel note the potential uplift from successful new product launches. However, sensitivity to procedure volumes and measured growth expectations temper enthusiasm. Alcidion is exploring M&A opportunities aligned with its growth pillars and reaffirmed guidance expects fiscal 2026 revenue to exceed A$50 million. This positions Alcidion as a smaller health tech stock navigating a complex medtech valuation environment with a steady but watchful investment narrative.

Latest article

Lockheed Martin Gets Golden Dome Opening as Profit Worries Bite

Lockheed Martin Gets Golden Dome Opening as Profit Worries Bite

26 April 2026
Lockheed Martin was named among firms awarded up to $3.2 billion for President Trump’s Golden Dome space-based missile interceptor plan, Space Systems Command said. The company reported weaker first-quarter results, with $18 billion in sales and negative free cash flow. Space Force aims to show initial interceptor capability in 2028. Golden Dome’s total cost is projected at $185 billion.
ASML Stock’s AI Boom Has a Catch: TSMC Won’t Rush the $410 Million Machine

ASML Stock’s AI Boom Has a Catch: TSMC Won’t Rush the $410 Million Machine

26 April 2026
ASML shares rose 2.3% in Amsterdam late Friday as the company reported Q1 net sales of €8.8 billion and raised its 2026 sales outlook to up to €40 billion. TSMC, ASML’s top customer, said it would delay adopting ASML’s new High-NA EUV machines, priced at over €350 million each, preferring to extend use of existing tools. ASML aims to deliver at least 60 standard EUV machines in 2026.
Shell stock price in focus: oil drops 1% ahead of London open, Iran talks loom
Previous Story

Shell stock price in focus: oil drops 1% ahead of London open, Iran talks loom

Rackspace (RXT) stock back in play as Palantir AI deal meets earnings week
Next Story

Rackspace (RXT) stock back in play as Palantir AI deal meets earnings week

Go toTop